For any serious research into accelerated recovery, this dual-action approach is a game-changer
Research shows that patients who discontinue GLP-1 therapy experience an average weight regain of 50-70% of lost weight within one year
Recent studies highlight how GLP-1 receptor agonistsincluding Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound)exhibit powerful anti-inflammatory effects
doi: 10.3389/fphar.2025.1654372 Received 26 June 2025 Accepted 05 August 2025 Published 18 August 2025 Volume 16 - 2025 Edited by Abbas Choudhury, VIT University, India Reviewed by Evelyn Weaver, The Pennsylvania State University (PSU), United States Marcelo Adrian Estrin, Interamerican Open University, Argentina Updates Copyright 2025 Zeng, Luo, Ou, Gan, Huang, Tomlinson and Jiang